Hero

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

1

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Celyad Reports First Half 2017 Financial Results and Operational Progress

2

Celyad Reports First Half 2017 Financial Results and Operational Progress

Celyad announces new agreements with Celdara Medical and Dartmouth College

3

Celyad announces new agreements with Celdara Medical and Dartmouth College

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

4

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

5

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

More info about Celyad

Latest News

Conference call - Update on Clinical Strategy

Conference call - Update on Clinical Strategy

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Celyad to Present at the Cantor Fitzgerald Global Healthcare Conference

Celyad to Present at the Cantor Fitzgerald Global Healthcare Conference

Discover all news

Carousel

Social Feed

#Biotech le guide de l'investisseur pour faire es bons choix @CelyadSA "Champion de la thérapie cellulaire" via @Le_Revenu

1 week ago

#Biotech le guide de l'investisseur pour faire es bons choix @CelyadSA "Champion de la thérapie cellulaire" via @Le_Revenu

#Biotech le guide de l'investisseur pour faire es bons choix @CelyadSA "Champion de la thérapie cellulaire" via… https://t.co/YOjfAn6kr1

1 week ago

#Biotech le guide de l'investisseur pour faire es bons choix @CelyadSA "Champion de la thérapie cellulaire" via… https://t.co/YOjfAn6kr1

#ICYMI @CelyadSA Conference Call - Update on clinical startegy https://t.co/vygWxnhjBo https://t.co/z5KvA1iFfU

1 week ago

#ICYMI @CelyadSA Conference Call - Update on clinical startegy https://t.co/vygWxnhjBo https://t.co/z5KvA1iFfU

#ICYMI @CelyadSA  Conference Call - Update on clinical startegy https://lnkd.in/eCX2qvF

1 week ago

#ICYMI @CelyadSA  Conference Call - Update on clinical startegy https://lnkd.in/eCX2qvF

#Biotech le guide de l'investisseur pour faire es bons choix @CelyadSA "Champion de la thérapie cellulaire" via… https://t.co/YOjfAn6kr1

1 week ago

#Biotech le guide de l'investisseur pour faire es bons choix @CelyadSA "Champion de la thérapie cellulaire" via… https://t.co/YOjfAn6kr1

#ICYMI @CelyadSA Conference Call - Update on clinical startegy https://t.co/vygWxnhjBo https://t.co/z5KvA1iFfU

1 week ago

#ICYMI @CelyadSA Conference Call - Update on clinical startegy https://t.co/vygWxnhjBo https://t.co/z5KvA1iFfU

Join @CelyadSA conference call today at 2:00pm (CEST) / 8:00am (EDT) #clinicalplan #update https://t.co/qVYrd3YHgs https://t.co/z6QcG7QH5P

2 weeks ago

Join @CelyadSA conference call today at 2:00pm (CEST) / 8:00am (EDT) #clinicalplan #update https://t.co/qVYrd3YHgs https://t.co/z6QcG7QH5P

[VIDEO] #PatrickJeanmart CFO de @CelyadSA revient sur la stratégie clinique de la société via @LaBourseEtLaVie… https://t.co/nzfQ8dMLRW

2 weeks ago

[VIDEO] #PatrickJeanmart CFO de @CelyadSA revient sur la stratégie clinique de la société via @LaBourseEtLaVie… https://t.co/nzfQ8dMLRW

#Biotech le guide de l'investisseur pour faire es bons choix @CelyadSA "Champion de la thérapie cellulaire" via @Le_Revenu

1 week ago

#Biotech le guide de l'investisseur pour faire es bons choix @CelyadSA "Champion de la thérapie cellulaire" via @Le_Revenu

#ICYMI @CelyadSA  Conference Call - Update on clinical startegy https://lnkd.in/eCX2qvF

1 week ago

#ICYMI @CelyadSA  Conference Call - Update on clinical startegy https://lnkd.in/eCX2qvF

Join #Celyad’s conference call today at 2:00pm (CEST) / 8:00am (EDT) to know more about our upcoming clinical plan! Dr. David Sallman from the Moffitt Cancer Center will also shed some light on the recently announced AML results.

2 weeks ago

Join #Celyad’s conference call today at 2:00pm (CEST) / 8:00am (EDT) to know more about our upcoming clinical plan! Dr. David Sallman from the Moffitt Cancer Center will also shed some light on the recently announced AML results.

Patrick Jeanmart Directeur Financier Celyad : "Optimiser notre programme de développement clinique"

2 weeks ago

Patrick Jeanmart Directeur Financier Celyad : "Optimiser notre programme de développement clinique"